Cancer is the 2nd major cause of human morbidity and mortality. Thus, PhDs and MD/PhDs specifically trained in the discipline of Cancer Biology and professionally involved in cancer research and education are a critical national health need. It is our view that an interdisciplinary graduate curriculum with a major focus upon the biology of cancer that interfaces with clinicians engaged in cancer diagnosis and treatment provides an excellent means of training specialists with a sufficient breadth of perspective for successful independent careers in cancer research and education. This is an application for renewal of a training grant, currently in its 25th year, to support 6 pre-doctoral students principally from the Cancer Biology Graduate Program (CBGP) in the Department of Oncology at the Wayne State University (WSU) and the Barbara Ann Karmanos Cancer Institute (KCI). Trainees include both PhD and MD/PhD candidates and are selected from our diverse student population, including underrepresented minorities. Training draws from the outstanding clinical and research facilities at WSU/KCI and the expertise of 19 accomplished training faculty in areas ranging from neoplastic development, and invasion and metastasis, to cancer therapy, prevention, and cancer epidemiology. A cornerstone of our training environment is the CPGB, which provides a unique educational experience that integrates extended cancer courses, seminars by local and nationally/internationally recognized speakers, student-faculty research retreats, attendance at national/international meetings, and specialized workshops and courses, ultimately culminating in a PhD in Cancer Biology. Graduate students have the opportunity to become familiar with state-of-the- art concepts and methods in molecular and cell biology research, and with cutting-edge technologies through the KCI research cores, and receive clinical exposures to the cancer problem by rounding with oncologists at the KCI Cancer Hospital. Specialized training in responsible conduct of research, grant writing, lab management, and career options are also provided. Training of our most outstanding graduate candidates from the CBGP is clearly enhanced by their competing for appointment to this NCI-sponsored training grant, thus equipping them to pursue successful careers in cancer research. During the previous 24 years of support, T32 CA009351 has trained an impressive group of cancer biologists who are substantially contributing to basic and translational cancer research and educational efforts at universities and research institutes throughout the United States.
Cancer is the 2nd major cause of human morbidity and mortality. Consequently, PhD and MD/PhD researchers specifically trained in the discipline of Cancer Biology and professionally involved in cancer research and educational are a critical national health need. This training grant, currently in its 25th year of continuous funding, is a cornerstone of a unique interdisciplinary graduate program designed to train the next generation of cancer biologists to meet this urgent national need.
|McFall, Thomas; McKnight, Brooke; Rosati, Rayna et al. (2018) Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. J Biol Chem 293:1163-1177|
|Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963|
|Jones, Steven K; Douglas, Kirk; Shields, Anthony F et al. (2018) Correlating quantitative tumor accumulation and gene knockdown using SPECT/CT and bioluminescence imaging within an orthotopic ovarian cancer model. Biomaterials 178:183-192|
|Guastella, Anthony R; Michelhaugh, Sharon K; Klinger, Neil V et al. (2018) Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors. J Neurooncol 139:239-249|
|Saadat, Nadia; Liu, Fangchao; Haynes, Brittany et al. (2018) Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy. Mol Cancer Ther 17:2586-2597|
|Heyza, Joshua; Lei, Wen; Watza, Donovan et al. (2018) Identification and characterization of synthetic viability with ERCC1 deficiency in response to interstrand crosslinks in lung cancer. Clin Cancer Res :|
|Ravindra, Manasa; Wilson, Mike R; Tong, Nian et al. (2018) Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor ? and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis. J Med Chem 61:4228-4248|
|McKnight, Brooke N; Viola-Villegas, Nerissa T (2018) 89 Zr-ImmunoPET companion diagnostics and their impact in clinical drug development. J Labelled Comp Radiopharm 61:727-738|
|Herroon, Mackenzie K; Rajagurubandara, Erandi; Diedrich, Jonathan D et al. (2018) Adipocyte-activated oxidative and ER stress pathways promote tumor survival in bone via upregulation of Heme Oxygenase 1 and Survivin. Sci Rep 8:40|
|Blocker, Stephanie J; Shields, Anthony F (2018) Imaging of Nanoparticle Distribution to Assess Treatments That Alter Delivery. Mol Imaging Biol 20:340-351|
Showing the most recent 10 out of 164 publications